Metex (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the regeneration of tetrahydrofolate needed for purine and thymidylate synthesis. This limits DNA, RNA and protein production in rapidly dividing cells, producing immunosuppressive effects in autoimmune disease and antiproliferative effects against malignant cells.

The dose of Metex is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Healthcare professionals determine the appropriate amount, frequency and titration schedule according to current clinical guidelines and patient monitoring results.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because of a high risk of fetal malformations and miscarriage. It is also not recommended while breastfeeding, as it can be excreted in milk and may harm the infant.

To request Metex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The primary alternatives to methotrexate are biologic DMARDs such as adalimumab or etanercept. While biologics target specific cytokines, methotrexate offers a broad immunosuppressive effect, is less costly, and is often used as first‑line therapy. Some patients may require combination therapy if response to methotrexate alone is insufficient.

Metex must be stored in a refrigerator at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours before use.

Metex is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose using a suitable needle, typically into the upper arm, thigh or abdomen. The injection site should be rotated to minimise local irritation, and aseptic technique must be observed throughout the procedure.

The most critical risks include severe infection due to immunosuppression, pulmonary toxicity such as interstitial pneumonitis, significant liver injury (fibrosis or cirrhosis), and bone‑marrow suppression leading to pancytopenia. Patients should report persistent fever, respiratory symptoms, jaundice or unusual bruising immediately.

Metex is contraindicated in pregnant or breastfeeding individuals, patients with severe hepatic disease, uncontrolled renal impairment, active infections, or known hypersensitivity to methotrexate or any excipients. Caution is also advised for patients with a history of lung disease or those receiving other myelosuppressive agents.